Thankfully, there are currently two RSV vaccines approved by the Food and Drug Administration to help people protect against the virus: Arexvy by GlaxoSmithKline and Abrysvo by Pfizer. The Centers for ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

Big pharma has long been a force for commercial broadcasters. Promotions for GSK’s respiratory vaccine Arexvy and its blockbuster shingles shot Shingrix are a big presence. But despite all the ...

“We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted Arexvy, indicating our potential best-in-class ...

GSK stock crumbled on Wednesday after vaccine sales tumbled, leading to a third-quarter miss. Revenue from RSV shot Arexvy ...